Issues related to the disease of diabetes, diabetes therapies, automated insulin delivery devices, and management of the disease of diabetes. Issues related to medical devices and medical device technologies. Issues related to Pharmacy Benefit Manager (PBM) reform proposals, PBM transparency and potential PBM proposals related to budget reconciliation package. Issues related to the reintroduction or possible reintroduction of the DIABETES Act in the 119th Congress. Issues related to artificial intelligence (AI) and predictive algorithms in medical devices and medical device technology. Issues related to tariffs and trade. Issues related to Local Coverage Determination revisions specifically in pathways for Continuous Glucose Monitors (CGM).
2025 · 1st Quarter (Jan 1 - Mar 31)
INSULET CORPORATION
Filed by INSULET CORPORATION.
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 17, 2025
- Income
- Not reported
- Expenses
- $40,000.00
- Registrant
- INSULET CORPORATION
- Client
- INSULET CORPORATION
- Filing UUID
- 9cf16bca-d7c0-4719-a7d2-b9234bf52786
- Termination date
- Not reported
Expense method: A
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.